Dolores González-Pacanowska

Dr. Dolores González-Pacanowska


Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2003 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JSJohn M. Sanders
John M. Sanders
AGAurora Ortiz Gómez
Aurora Ortiz Gómez
JMJunhong Mao
Junhong Mao
GMGary A. Meints
Gary A. Meints
EBErin M. Van Brussel
Erin M. Van Brussel
EOEric Oldfield
Eric Oldfield

20 September 2003 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FMFilippo Magaraci
Filippo Magaraci
CJCarmen Jimenez Jimenez
Carmen Jimenez Jimenez
CRCarlos Rodrigues
Carlos Rodrigues
JRJuliany Cola Fernandes Rodrigues
Juliany Cola Fernandes Rodrigues
MBMarina Vianna Braga
Marina Vianna Braga
IGIan H Gilbert
Ian H Gilbert

1 February 2005 in Structure
Verified
Journal Article
Closed access
JWJean L. Whittingham
Jean L. Whittingham
ILIsabel Leal
Isabel Leal
CNCorinne Nguyen
Corinne Nguyen
GKGanasan Kasinathan
Ganasan Kasinathan
EBEmma Bell
Emma Bell
KWKeith S. Wilson
Keith S. Wilson

12 September 2014 in Journal of Natural Products
Verified
Journal Article
Closed access
JSJesús Martín Serrano
Jesús Martín Serrano
GCGloria Crespo
Gloria Crespo
Gonzalez-Menendez VíctorGonzalez-Menendez Víctor
Gonzalez-Menendez Víctor
GPGuiomar Pérez-Moreno
Guiomar Pérez-Moreno
PSPaula Sánchez-Carrasco
Paula Sánchez-Carrasco
Fernando ReyesFernando Reyes
Fernando Reyes

1 January 2015 in SLAS Discovery
Verified
Journal Article
Open access
Frederick Boye AnnangFrederick Boye Annang
Frederick Boye Annang
GPG. Pérez-Moreno
G. Pérez-Moreno
RGR. García-Hernández
R. García-Hernández
CCC. Cordon-Obras
C. Cordon-Obras
JSJesús Martín Serrano
Jesús Martín Serrano
DGDolores González-Pacanowska
Dolores González-Pacanowska
African trypanosomiasis, leishmaniasis, and Chagas disease are 3 neglected tropical diseases for which current therapeutic interventions are inadequate or toxic. There is an urgent need to find new lead compounds against these diseases. Most drug discovery strategies rely on high-throughput screening (HTS) of synthetic chemical libraries using phenotypic and target-based approaches. Combinatorial chemistry libraries contain hundreds of thousands of compounds; however, they lack the structural diversity required to find entirely novel chemotypes. Natural products, in contrast, are a highly underexplored pool of unique chemical diversity that can serve as excellent templates for the synthesis of novel, biologically active molecules. We report here a validated HTS platform for the screening of microbial extracts against the 3 diseases. We have used this platform in a pilot project to screen a subset (5976) of microbial extracts from the MEDINA Natural Products library. Tandem liquid chromatography–mass spectrometry showed that 48 extracts contain potentially new compounds that are currently undergoing de-replication for future isolation and characterization. Known active components included actinomycin D, bafilomycin B1, chromomycin A3, echinomycin, hygrolidin, and nonactins, among others. The report here is, to our knowledge, the first HTS of microbial natural product extracts against the above-mentioned kinetoplastid parasites.

1 August 2004 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
SLSilvia Orenes Lorente
Silvia Orenes Lorente
JRJuliany Cola Fernandes Rodrigues
Juliany Cola Fernandes Rodrigues
CJCarmen JiménEz JiménEz
Carmen JiménEz JiménEz
MJMiranda Joyce-Menekse
Miranda Joyce-Menekse
CRCarlos Rodrigues
Carlos Rodrigues
IGIan H. Gilbert
Ian H. Gilbert
This paper describes the design and evaluation of novel azasterols as potential compounds for the treatment of leishmaniasis and other diseases caused by trypanosomatid parasites. Azasterols are a known class of ( S )-adenosyl- l -methionine: Δ 24 -sterol methyltransferase(24-SMT) inhibitors in fungi, plants, and some parasitic protozoa. The compounds prepared showed activity at micromolar and nanomolar concentrations when tested against Leishmania spp. and Trypanosoma spp. The enzymatic and sterol composition studies indicated that the most active compounds acted by inhibiting 24-SMT. The role of the free hydroxyl group at position 3 of the sterol nucleus was also probed. When an acetate was attached to the 3β-OH, the compounds did not inhibit the enzyme but had an effect on parasite growth and the levels of sterols in the parasite, suggesting that the acetate group was removed in the organism. Thus, an acetate group on the 3β-OH may have application as a prodrug. However, there may be an additional mode(s) of action for these acetate derivatives. These compounds were shown to have ultrastructural effects on Leishmania amazonensis promastigote membranes, including the plasma membrane, the mitochondrial membrane, and the endoplasmic reticulum. The compounds were also found to be active against the bloodstream form (trypomastigotes) of Trypanosoma brucei rhodesiense , a causative agent of African trypanosomiasis.